Whole genome sequence analysis of Salmonella Typhi in Papua New Guinea reveals an established population of genotype 2.1.7 sensitive to antimicrobials.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
26
09
2021
accepted:
05
03
2022
revised:
07
04
2022
pubmed:
29
3
2022
medline:
12
4
2022
entrez:
28
3
2022
Statut:
epublish
Résumé
Typhoid fever, a systemic infection caused by Salmonella enterica serovar Typhi, remains a considerable public health threat in impoverished regions within many low- and middle-income settings. However, we still lack a detailed understanding of the emergence, population structure, molecular mechanisms of antimicrobial resistance (AMR), and transmission dynamics of S. Typhi across many settings, particularly throughout the Asia-Pacific islands. Here we present a comprehensive whole genome sequence (WGS) based overview of S. Typhi populations circulating in Papua New Guinea (PNG) over 30 years. Bioinformatic analysis of 86 S. Typhi isolates collected between 1980-2010 demonstrated that the population structure of PNG is dominated by a single genotype (2.1.7) that appears to have emerged in the Indonesian archipelago in the mid-twentieth century with minimal evidence of inter-country transmission. Genotypic and phenotypic data demonstrated that the PNG S. Typhi population appears to be susceptible to former first line drugs for treating typhoid fever (chloramphenicol, ampicillin and co-trimoxazole), as well as fluoroquinolones, third generation cephalosporins, and macrolides. PNG genotype 2.1.7 was genetically conserved, with very few deletions, and no evidence of plasmid or prophage acquisition. Genetic variation among this population was attributed to either single point mutations, or homologous recombination adjacent to repetitive ribosomal RNA operons. Antimicrobials remain an effective option for the treatment of typhoid fever in PNG, along with other intervention strategies including improvements to water, sanitation and hygiene (WaSH) related infrastructure and potentially the introduction of Vi-conjugate vaccines. However, continued genomic surveillance is warranted to monitor for the emergence of AMR within local populations, or the introduction of AMR associated genotypes of S. Typhi in this setting.
Sections du résumé
BACKGROUND
Typhoid fever, a systemic infection caused by Salmonella enterica serovar Typhi, remains a considerable public health threat in impoverished regions within many low- and middle-income settings. However, we still lack a detailed understanding of the emergence, population structure, molecular mechanisms of antimicrobial resistance (AMR), and transmission dynamics of S. Typhi across many settings, particularly throughout the Asia-Pacific islands. Here we present a comprehensive whole genome sequence (WGS) based overview of S. Typhi populations circulating in Papua New Guinea (PNG) over 30 years.
PRINCIPLE FINDINGS
Bioinformatic analysis of 86 S. Typhi isolates collected between 1980-2010 demonstrated that the population structure of PNG is dominated by a single genotype (2.1.7) that appears to have emerged in the Indonesian archipelago in the mid-twentieth century with minimal evidence of inter-country transmission. Genotypic and phenotypic data demonstrated that the PNG S. Typhi population appears to be susceptible to former first line drugs for treating typhoid fever (chloramphenicol, ampicillin and co-trimoxazole), as well as fluoroquinolones, third generation cephalosporins, and macrolides. PNG genotype 2.1.7 was genetically conserved, with very few deletions, and no evidence of plasmid or prophage acquisition. Genetic variation among this population was attributed to either single point mutations, or homologous recombination adjacent to repetitive ribosomal RNA operons.
SIGNIFICANCE
Antimicrobials remain an effective option for the treatment of typhoid fever in PNG, along with other intervention strategies including improvements to water, sanitation and hygiene (WaSH) related infrastructure and potentially the introduction of Vi-conjugate vaccines. However, continued genomic surveillance is warranted to monitor for the emergence of AMR within local populations, or the introduction of AMR associated genotypes of S. Typhi in this setting.
Identifiants
pubmed: 35344544
doi: 10.1371/journal.pntd.0010306
pii: PNTD-D-21-01426
pmc: PMC8989336
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0010306Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106158/Z/14/Z
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Antimicrob Agents Chemother. 2014;58(1):212-20
pubmed: 24145532
Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S4-S9
pubmed: 30767000
Clin Infect Dis. 2020 Nov 5;71(8):1856-1863
pubmed: 32003431
Nucleic Acids Res. 2011 May;39(9):e57
pubmed: 21306991
PLoS Negl Trop Dis. 2018 Apr 23;12(4):e0006408
pubmed: 29684021
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S775-S780
pubmed: 34453548
Bioinformatics. 2014 Jul 15;30(14):2068-9
pubmed: 24642063
Bioinformatics. 2015 Oct 15;31(20):3350-2
pubmed: 26099265
Elife. 2016 Mar 11;5:e14003
pubmed: 26974227
PLoS Negl Trop Dis. 2020 Feb 27;14(2):e0008036
pubmed: 32106221
N Engl J Med. 2002 Nov 28;347(22):1770-82
pubmed: 12456854
P N G Med J. 1995 Dec;38(4):305-14
pubmed: 9522873
Genome Med. 2014 Nov 20;6(11):90
pubmed: 25422674
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S165-S170
pubmed: 30845331
Mol Biol Evol. 2010 Sep;27(9):2038-51
pubmed: 20363828
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
J Clin Microbiol. 2002 Nov;40(11):4156-60
pubmed: 12409390
P N G Med J. 2005 Sep-Dec;48(3-4):158-67
pubmed: 17212062
Lancet Infect Dis. 2005 Oct;5(10):623-8
pubmed: 16183516
J Antimicrob Chemother. 2020 Feb 1;75(2):337-341
pubmed: 31665304
Lancet Microbe. 2022 Aug;3(8):e567-e577
pubmed: 35750070
Rev Infect Dis. 1985 Mar-Apr;7(2):244-56
pubmed: 3890097
Bioinformatics. 2014 May 1;30(9):1312-3
pubmed: 24451623
mBio. 2011 Jun 07;2(3):e00060-11
pubmed: 21652779
Trends Genet. 2000 Jun;16(6):276-7
pubmed: 10827456
Bioinformatics. 2010 Sep 15;26(18):2334-5
pubmed: 20624783
J Mol Biol. 2004 May 28;339(2):279-300
pubmed: 15136033
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595
pubmed: 28594827
PLoS Negl Trop Dis. 2019 Sep 12;13(9):e0007620
pubmed: 31513580
mSphere. 2020 Jul 22;5(4):
pubmed: 32699118
PLoS Comput Biol. 2014 Apr 10;10(4):e1003537
pubmed: 24722319
Microbiol Mol Biol Rev. 2004 Sep;68(3):560-602, table of contents
pubmed: 15353570
J Bacteriol. 2012 Sep;194(18):5122-3
pubmed: 22933755
BMC Health Serv Res. 2017 Jan 5;17(1):10
pubmed: 28056949
Electrophoresis. 1998 Apr;19(4):569-72
pubmed: 9588803
Microorganisms. 2020 Sep 01;8(9):
pubmed: 32883020
PLoS Negl Trop Dis. 2016 Sep 22;10(9):e0004781
pubmed: 27657909
Nucleic Acids Res. 2016 Jul 8;44(W1):W16-21
pubmed: 27141966
P N G Med J. 1995 Dec;38(4):300-4
pubmed: 9522872
Nat Genet. 2008 Aug;40(8):987-93
pubmed: 18660809
Nature. 2001 Oct 25;413(6858):848-52
pubmed: 11677608
Nat Commun. 2018 Nov 30;9(1):5094
pubmed: 30504848
Nat Methods. 2012 Mar 04;9(4):357-9
pubmed: 22388286
Antimicrob Agents Chemother. 2014 Jul;58(7):3895-903
pubmed: 24777092
mBio. 2021 Feb 16;12(1):
pubmed: 33593966
Lancet Infect Dis. 2019 Apr;19(4):369-381
pubmed: 30792131
Microb Genom. 2017 Sep 14;3(10):e000132
pubmed: 29177090
Genome Res. 2004 Jul;14(7):1394-403
pubmed: 15231754
Clin Infect Dis. 2021 Mar 1;72(5):e120-e127
pubmed: 33515460
Curr Protoc Bioinformatics. 2003 Feb;Chapter 10:Unit 10.3
pubmed: 18428693
JAC Antimicrob Resist. 2020 Dec 21;2(4):dlaa109
pubmed: 34223059
Nat Genet. 2015 Jun;47(6):632-9
pubmed: 25961941
PLoS Negl Trop Dis. 2019 Nov 15;13(11):e0007868
pubmed: 31730615
Microb Genom. 2020 Jul;6(7):
pubmed: 32584752
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29180525
Elife. 2021 Sep 13;10:
pubmed: 34515028
Microb Genom. 2016 Nov 30;2(11):e000094
pubmed: 28348834
J Clin Microbiol. 1996 Apr;34(4):1029-33
pubmed: 8815078
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Commun. 2016 Oct 05;7:12827
pubmed: 27703135
J Antimicrob Chemother. 2021 Apr 13;76(5):1160-1167
pubmed: 33347558
Microb Genom. 2016 Nov 30;2(11):e000093
pubmed: 28348833
Infect Genet Evol. 2018 Oct;64:52-56
pubmed: 29906636
Clin Vaccine Immunol. 2012 Nov;19(11):1833-7
pubmed: 22993409
Nucleic Acids Res. 2015 Feb 18;43(3):e15
pubmed: 25414349